NCT02968732Active, not recruiting
Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder
Assessment of Reliability of Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder at the Time of Radical Cystectomy
Source: ClinicalTrials.gov · Last updated 21 Sept 2026
Brief summary (registry, in English)
A prospective, investigational study to assess the accuracy of standardized cystoscopic evaluation with tissue sampling performed immediately prior to definitive radical cystectomy to predict pathologic tumor stage and identify patients who may benefit from bladder preservation therapy.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 65 (actual)
- First submitted
- 10 Nov 2016
- Start date
- 11 Nov 2016
- Primary completion date
- 19 Aug 2019
- Lead sponsor
- Fox Chase Cancer Center
- Diseases
- Bladder cancer
- NCT number
- NCT02968732
What you commit to
- Study type: Interventional
- Participants enrolled: 65
- From 11 Nov 2016 to the primary completion date, 19 Aug 2019
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have undergone any prior pelvic irradiation.
Other
- Patients who undergo cystectomy with non-curative intent will be excluded.
- Patients who are pregnant or nursing. Radical cystectomy and prolonged general anesthesia would place the fetus at considerable risk of demise. The prolonged recovery and debility of the patient would severely limit the patient's ability to nurse and care for an infant.
Who the study is looking for
- Male or female patients age \>18 years at the time of consent.
- Patients with a diagnosis of urothelial carcinoma clinical stage T1-T4NanyM0.
- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3.
- Patients must have a clinical decision to proceed with radical cystectomy by any conventional approach (open, laparoscopic, robot-assisted laparoscopic). Time from decision to surgery is usually 3-8 weeks for those who do not receive neoadjuvant chemotherapy and 10-14 weeks for those who receive neo-adjuvant chemotherapy treatment. During this time, eligibility for study participation will be verified.
- Ability to understand and willingness to sign a written informed consent and HIPAA authorization document or a legally authorized representative who has the ability to understand and willingness to sign a written informed consent and HIPAA authorization on behalf of the participant.
- Women of reproductive potential must have agreed to use an effective contraceptive measure.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fox Chase Cancer Center Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.